FDA Approved: CARBINOXAMINE MALEATE EXTENDED-RELEASE ORAL SUSPENSION — Supplemental Application (Neos Therapeutics, LP)

View source ↗

Summary

FDA approved a supplemental application to authorize a new extended-release oral suspension formulation of carbinoxamine maleate by Neos Therapeutics, LP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis
• Allergic Rhinitis
• Urticaria

Drugs mentioned

• Carbinoxamine maleate extended-release oral suspension (carbinoxamine maleate)

Snippet

SUPPL AP for CARBINOXAMINE MALEATE EXTENDED-RELEASE ORAL SUSPENSION (CARBINOXAMINE MALEATE)